Dr Reddy’s receives inspection closures report from USFDA for Duvada facility

This site was included in the warning letter received from the USFDA in November 2015.

Feb 17, 2019 09:02 IST India Infoline News Service

Dr. Reddy’s, in its press note to the exchanges on Saturday, informed that the company has received inspection closure report from the United States Food and Drug Administration (USFDA) about the issuance of establishment inspection report (EIR) for its Duvada facility.

"We have received a written communication from the USFDA, about the issuance of EIR for FTO VII, our formulations manufacturing facility at Duvvada, Visakhapatnam," the company said in a press note.

This site was included in the warning letter received from the USFDA in November 2015.

Subsequently, the site was audited by USFDA in March 2017 for which the company received EIR in November 2017, wherein the site's status remained unchanged. The site was again audited in October 2018.

"Based on our responses and follow up actions, the USFDA has concluded that this inspection is closed and has determined the inspection classification of this facility as Voluntary Action Initiated (VAi)," the company added.

Dr Reddys Laboratories' share price ended at Rs2,556.90, down by Rs112.4 or 4.21%, from its previous close of Rs2,669.30 on the BSE.
The scrip opened at Rs2,650.10 and touched a high and low of Rs2,650.10 and Rs2,065.30, respectively. A total of, 72,50,230 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs42,460.10cr.

Related Story

Open Free Demat Account (Rs699)